Circulating Cell-Free DNA as a potential Diagnostic Tool in Pancreatic Cancer: A Comparative Analysis.

IF 1.2 3区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Digestive Surgery Pub Date : 2025-09-23 DOI:10.1159/000547870

Romualdas Riauka, Rita Kupcinskaite-Noreikiene, Ingrida Grabauskyte, Antanas Gulbinas, Giedrius Barauskas, Aldona Jasukaitiene, Vakare Gruodyte, Povilas Ignatavicius

{"title":"Circulating Cell-Free DNA as a potential Diagnostic Tool in Pancreatic Cancer: A Comparative Analysis.","authors":"Romualdas Riauka, Rita Kupcinskaite-Noreikiene, Ingrida Grabauskyte, Antanas Gulbinas, Giedrius Barauskas, Aldona Jasukaitiene, Vakare Gruodyte, Povilas Ignatavicius","doi":"10.1159/000547870","DOIUrl":null,"url":null,"abstract":"Introduction: Liquid biopsies enable non-invasive tumor material sampling in patients with pancreatic adenocarcinoma (PDAC). Genetic information, especially alterations in circulating free DNA (cfDNA) levels, might help to predict poorer tumor differentiation, disease progression and might be used as treatment efficacy evaluator. However, the data on this topic is insufficient.Methods: Newly diagnosed, PDAC patients without prior systemic treatment and chronic pancreatitis patients treated at the tertiary university hospital and healthy controls were included in this prospective study. Blood samples were collected pre-treatment, and cfDNA was extracted and measured using necessary equipment according to manufacturer's protocols.Results: 57 patients (47 PDAC and 10 chronic pancreatitis) and 8 healthy controls were included. cfDNA levels were significantly higher in cancer patients compared to chronic pancreatitis (p = 0,032) and healthy controls (p < 0.001). The determined cfDNA cut-off value for distinguishing PDAC from chronic pancreatitis was 23.65 ng/ml and for distinguishing PDAC from healthy controls - 22.9 ng/ml. However, no distinctions in cfDNA levels were noted concerning tumor characteristics or survival rates.Conclusion: Liquid biopsies and alterations in cfDNA levels could aid in distinguishing PDAC from benign inflammatory diseases or healthy patients. Nonetheless, further studies are necessary for more comprehensive validation.","PeriodicalId":11241,"journal":{"name":"Digestive Surgery","volume":" ","pages":"1-15"},"PeriodicalIF":1.2000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547870","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Liquid biopsies enable non-invasive tumor material sampling in patients with pancreatic adenocarcinoma (PDAC). Genetic information, especially alterations in circulating free DNA (cfDNA) levels, might help to predict poorer tumor differentiation, disease progression and might be used as treatment efficacy evaluator. However, the data on this topic is insufficient.

Methods: Newly diagnosed, PDAC patients without prior systemic treatment and chronic pancreatitis patients treated at the tertiary university hospital and healthy controls were included in this prospective study. Blood samples were collected pre-treatment, and cfDNA was extracted and measured using necessary equipment according to manufacturer's protocols.

Results: 57 patients (47 PDAC and 10 chronic pancreatitis) and 8 healthy controls were included. cfDNA levels were significantly higher in cancer patients compared to chronic pancreatitis (p = 0,032) and healthy controls (p < 0.001). The determined cfDNA cut-off value for distinguishing PDAC from chronic pancreatitis was 23.65 ng/ml and for distinguishing PDAC from healthy controls - 22.9 ng/ml. However, no distinctions in cfDNA levels were noted concerning tumor characteristics or survival rates.

Conclusion: Liquid biopsies and alterations in cfDNA levels could aid in distinguishing PDAC from benign inflammatory diseases or healthy patients. Nonetheless, further studies are necessary for more comprehensive validation.

查看原文本刊更多论文

循环游离细胞DNA作为胰腺癌的潜在诊断工具：比较分析。

液体活检能够对胰腺腺癌（PDAC）患者进行非侵入性肿瘤物质取样。遗传信息，特别是循环游离DNA （cfDNA）水平的改变，可能有助于预测较差的肿瘤分化、疾病进展，并可能用作治疗效果评估指标。然而，关于这个主题的数据是不足的。方法：本前瞻性研究纳入新诊断、未接受系统治疗的PDAC患者、在第三大学医院治疗的慢性胰腺炎患者和健康对照者。预处理前采集血样，使用必要的设备根据制造商的方案提取和测量cfDNA。结果：57例患者（47例PDAC， 10例慢性胰腺炎）和8例健康对照。与慢性胰腺炎（p = 0,032）和健康对照组（p < 0.001）相比，癌症患者的cfDNA水平明显更高。鉴别PDAC与慢性胰腺炎的cfDNA临界值为23.65 ng/ml，鉴别PDAC与健康对照的cfDNA临界值为22.9 ng/ml。然而，cfDNA水平与肿瘤特征或生存率没有显著差异。结论：液体活检和cfDNA水平的改变有助于区分PDAC与良性炎症性疾病或健康患者。然而，需要进一步的研究来进行更全面的验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Digestive Surgery 医学-外科

CiteScore

4.90

自引率

3.70%

发文量

审稿时长

3 months

期刊介绍： ''Digestive Surgery'' presents a comprehensive overview in the field of gastrointestinal surgery. Interdisciplinary in scope, the journal keeps the specialist aware of advances in all fields that contribute to improvements in the diagnosis and treatment of gastrointestinal disease. Particular emphasis is given to articles that evaluate not only recent clinical developments, especially clinical trials and technical innovations such as new endoscopic and laparoscopic procedures, but also relevant translational research. Each contribution is carefully aligned with the need of the digestive surgeon. Thus, the journal is an important component of the continuing medical education of surgeons who want their practice to benefit from a familiarity with new knowledge in all its dimensions.